Axsome Therapeutics' ADHD drug meets main goal in late-stage study
ReutersMar 25, 2025 11:09 AM
March 25 (Reuters) - Axsome Therapeutics AXSM.O said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
January CPI Revives Rate-Cut Hopes; Gold and Silver Rebound, But Is the Bull Run Intact?
TradingKey - During Friday's US session, spot gold surged back above $5,000 to close at $5,043, while silver resumed its rally, breaking through the $75 mark to peak near $79 before closing at $77.43. This movement was primarily driven by data from the U.S. Bureau of Labor Statistics that significanTradingKey
8 hours ago
SpaceX IPO with Dual-Class Shares: Will Musk Secure the 25% Voting Control Denied by Tesla?
TradingKey - SpaceX is preparing for an IPO this year. According to foreign media reports, SpaceX is considering a dual-class share structure for its IPO, which would grant specific shareholders extra voting rights. In other words, Elon Musk could maintain absolute control over the company even if hTradingKey
Sat, Feb 14
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
